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Abstract
Pathogen-mediated balancing selection is regarded as a key driver of host immunogenetic diversity. A hallmark for
balancing selection in humans is the heterozygote advantage at genes of the human leukocyte antigen (HLA), resulting in
improved HIV-1 control. However, the actual mechanism of the observed heterozygote advantage is still elusive. HLA
heterozygotes may present a broader array of antigenic viral peptides to immune cells, possibly resulting in a more
efficient cytotoxic T-cell response. Alternatively, heterozygosity may simply increase the chance to carry the most
protective HLA alleles, as individual HLA alleles are known to differ substantially in their association with HIV-1 control.
Here, we used data from 6,311 HIV-1-infected individuals to explore the relative contribution of quantitative and
qualitative aspects of peptide presentation in HLA heterozygote advantage against HIV. Screening the entire HIV-1
proteome, we observed that heterozygous individuals exhibited a broader array of HIV-1 peptides presented by their HLA
class I alleles. In addition, viral load was negatively correlated with the breadth of the HIV-1 peptide repertoire bound by
an individual’s HLA variants, particularly at HLA-B. This suggests that heterozygote advantage at HLA-B is at least in part
mediated by quantitative peptide presentation. We also observed higher HIV-1 sequence diversity among HLA-B het-
erozygous individuals, suggesting stronger evolutionary pressure from HLA heterozygosity. However, HLA heterozygotes
were also more likely to carry certain HLA alleles, including the highly protective HLA-B*57:01 variant, indicating that
HLA heterozygote advantage ultimately results from a combination of quantitative and qualitative effects in antigen
presentation.
Key words: major histocompatibility complex, MHC evolution, pathogen-mediated balancing selection, divergent
allele advantage, human leukocyte antigen, antigen presentation.
Introduction
Genes of the major histocompatibility complex (MHC) are a
core component of the vertebrate immune system and play a
central role in immune-recognition of pathogens. In humans,
the classical MHC genes are called human leukocyte antigen
(HLA) genes and reside in the MHC region on chromosome 6.
MHC genes encode cell-surface molecules that present intra-
and extracellular peptides to T cells, which, upon recognizing
them as nonself, initiate specific immune responses (Neefjes
et al. 2011). Each MHC molecule binds a specific peptide
repertoire which is largely defined by the amino acid
composition of its peptide-binding groove (Rao et al. 2011;
Neefjes and Ovaa 2013). Due to their key role in adaptive
immunity and unparalleled allelic diversity within and across
vertebrate species, MHC genes have become a paradigm for
studying the effect of genetic diversity on immu-
nocompetence and fitness (Nei and Hughes 1991; Sommer
2005; Trowsdale and Knight 2013). The dynamic action of
pathogen-mediated balancing selection is widely regarded as
a key driver of MHC diversity (Hedrick and Thomson 1983;
Apanius et al. 1997; Hughes and Yeager 1998; Solberg
et al. 2008; Lenz 2018). Three main mechanisms of
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pathogen-mediated balancing selection have been proposed:
“heterozygote advantage,” “rare-allele advantage,” and
“fluctuating selection,” all of which have received empirical
support (Sommer 2005; Eizaguirre and Lenz 2010; Spurgin
and Richardson 2010; Lenz 2018). It is also largely established
that these mechanisms are not mutually exclusive and likely
act in parallel to shape the MHC allele pool of a population.
However, the relative contribution of each of these mecha-
nisms is still debated and may indeed depend on the specific
conditions of a given population or species (Ejsmond and
Radwan 2015; Stutz and Bolnick 2017).
First proposed by Doherty and Zinkernagel (1975), the
heterozygote advantage hypothesis assumes that heterozy-
gous MHC genotypes confer a higher probability of triggering
a specific immune response upon infection. Heterozygosity
here (and throughout this article) is defined as carrying two
different homologous alleles at a given gene locus that code
for different variants of the corresponding molecule. This
would result in enhanced pathogen resistance for MHC het-
erozygous individuals, compared with MHC homozygotes,
promoting the persistence of different MHC alleles in the
population (Hughes and Yeager 1998; Penn et al. 2002).
One possible explanation for heterozygote advantage is the
presumed ability of MHC heterozygous individuals to present
a broader array of pathogen-derived peptides, thus increasing
the probability of inducing a targeted response. This would
result in overdominance, where a heterozygote does better
than either homozygote. This quantitative explanation for
heterozygote advantage has been expanded to the sequence
level, triggered by the frequently observed excessive sequence
divergence among MHC alleles: the “divergent allele
advantage” hypothesis (Potts and Wakeland 1990;
Wakeland et al. 1990). It assumes that individuals with
more divergent MHC allele combinations (i.e., higher number
of amino acid differences between the peptide-binding
domains of the two homologous MHC alleles) would express
MHC molecules with greater difference in their presented
peptide repertoires. This would result in a more diverse array
of presented peptides at the cell surface, conferring increased
immune-surveillance against pathogens (Lenz 2011; Pierini
and Lenz 2018). The observable extent of allele divergence
for a given locus can range from 0 (homozygous genotype) to
more than 25% of the amino acids in the peptide-binding
domain differing between the two alleles, where some alleles
that differ only by one or a few amino acids have near-
identical binding properties and could be considered homo-
zygous at the functional level. Considering allele divergence
instead of simple zygosity thus provides a more nuanced and
more functional approach to characterizing MHC variability.
An alternative explanation for heterozygote advantage,
based on qualitative differences between MHC alleles, stipu-
lates that heterozygosity increases the probability of carrying
specific protective MHC alleles. Such qualitative differences
among specific alleles have indeed been observed in a number
of species, including humans (Piertney and Oliver 2006;
Blackwell et al. 2009; Trowsdale 2011). However, it is unclear
whether these qualitative differences among MHC alleles re-
sult from unique peptide-binding properties (i.e., the ability to
present critical peptides) or whether they are also due to
quantitative differences in the size of the allele-specific anti-
gen repertoires (Chappell et al. 2015; Manczinger et al. 2019).
A number of studies across a range of species have pro-
vided empirical support for a phenotypic advantage con-
ferred by general MHC heterozygosity (Penn et al. 2002;
Takeshima et al. 2008; Evans and Neff 2009; Connor et al.
2010; Niskanen et al. 2014) as well as higher sequence diver-
gence between MHC alleles (Landry et al. 2001; Richman et al.
2001; Neff et al. 2008; Lenz et al. 2009, 2013; Schwensow et al.
2010). Humans have thousands of known alternative HLA
alleles (Solberg et al. 2008; Robinson et al. 2015, 2017), yet
empirical evidence for pathogen-mediated selection is sur-
prisingly sparse. Owing to the growing number of individuals
included in immunogenetic studies and to denser genotyping
approaches, multiple significant associations have been iden-
tified between infectious or immune phenotypes and varia-
tion in the MHC region (Trowsdale 2011; Matzaraki et al.
2017; Meyer et al. 2018). However, most association studies
assume simple additive genetic contributions and do not
explore the evolutionary implications of their findings, due
to a general focus on the underlying biology and disease
mechanisms. One of the few exceptions is the seminal study
on HIV control by Carrington et al. (1999), which demon-
strated a slower progression to HIV-related outcomes (AIDS-
defining conditions, CD4þ T-cell count <200 and/or death)
in HLA heterozygous individuals. Indeed, the role of HLA
genes in modulating spontaneous HIV control and progres-
sion to AIDS is now well established (Carrington and O’Brien
2003). Recently, the International Collaboration for the
Genomics of HIV aggregated an unprecedented data set of
HIV-infected individuals to fine-map the association between
HLA genetics and HIV control (McLaren et al. 2015). This
effort identified HLA-B as the major HLA locus in the associ-
ation with individual variation in HIV-1 set-point viral load
(spVL), with three amino acid residues in the antigen-binding
groove of HLA-B accounting for 11.4% of the variation, fol-
lowed by two residues of HLA-A accounting for an additional
0.9% of variation. These effects appeared to be largely driven
by substantial additive associations between various HLA
alleles and HIV viral load, but this work nevertheless revealed
a small independent protective effect of HLA-B heterozygos-
ity. Here, we are therefore revisiting this hallmark example for
MHC heterozygote advantage in humans and expand the
analysis to all classical HLA class I genes. Furthermore, we
characterize the heterozygote advantage at the functional
level and explore the relative effect of specific HLA alleles
versus a general effect of zygosity on HIV control. We thus
take advantage of the well-established association between
HLA and HIV control to test whether MHC heterozygote
advantage results from quantitative or qualitative differences
among MHC alleles. We use genotyping data from 6,311 HIV-
1-infected individuals and established antigen-binding predic-
tion algorithms for HLA class I proteins to define the individ-
ual repertoires of HIV-1 peptides bound by individual HLA-A,
HLA-B, and HLA-C molecule variants. We show that hetero-
zygosity at HLA-B and HLA-C but not at HLA-A is associated
with viral control. Although at HLA-B, the heterozygote
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advantage is potentially mediated by quantitative cytotoxic T
cell (CTL) response, another mechanism seems to operate at
HLA-C. Furthermore, we show that specific HLA alleles with
very strong effects exceed the general heterozygote advantage
against HIV-1.
Results
The available data comprised HLA genotypes and alleles (im-
puted at second field resolution, see Materials and Methods)
and pretreatment spVL, an established correlate of HIV-1
control and disease progression (Mellors et al. 1996), for
6,311 HIV-infected individuals of European descent. We fo-
cused on classical HLA class I genes (HLA-A, HLA-B, and HLA-
C), as they are the only genes within the MHC region reported
to be independently associated with HIV-1 progression
(Carrington et al. 1999; McLaren et al. 2015). A total of 37
HLA-A, 69 HLA-B, and 27 HLA-C alleles were represented in
the data set (supplementary tables S1–S3, Supplementary
Material online). Using an established algorithm for
peptide-binding prediction (NetMHCpan v4.0; Jurtz et al.
2017), we screened all possible 9mer HIV-1 peptides
(N¼ 3,252) across the HIV-1 proteome and identified 409,
491, and 223 distinct peptides predicted to be bound by at
least one of the represented HLA-A, HLA-B, and HLA-C alleles,
respectively (supplementary tables S1–S3, Supplementary
Material online).
HLA Heterozygote Advantage
We first tested whether heterozygosity at any of the classical
HLA class I loci was associated with better HIV-1 control (i.e.,
lower spVL), as reported previously (Carrington et al. 1999).
Indeed, we observed a lower level of viral load in both HLA-B
and HLA-C heterozygous individuals, compared with homo-
zygous individuals (Wilcox rank sum test, P¼ 1.3 106 and
2.8 106 for HLA-B and HLA-C, respectively, after correcting
for multiple testing), whereas heterozygosity at HLA-A
showed no statistically significant effect on spVL (Wilcox
rank sum test, P¼ 0.11) (fig. 1). Note, however, that even
though the associations for HLA-B and HLA-C were highly
significant, the actual effect of heterozygosity on viral load
was quite small (effect size ¼ 0.25 and –0.21, respectively).
In order to verify that the observed differences in viral load are
not caused by the unbalanced sample size for HLA heterozy-
gous and homozygous individuals, we randomly subsampled
HLA heterozygous individuals and compared their viral load
with an equal number of HLA homozygous individuals 1,000
times. This showed that the lower viral load in HLA hetero-
zygous individuals is not an artifact of unbalanced sample size
(supplementary fig. S1, Supplementary Material online).
The MHC region is characterized by strong linkage disequi-
librium (LD) between individual HLA genes (Ahmad et al.
2003; Stenzel et al. 2004; Blomhoff et al. 2006). To test whether
the observed effects of HLA-B and HLA-C heterozygosity were
independent, we calculated the association of HLA-B hetero-
zygosity with spVL among HLA-C heterozygotes only
(N¼ 5,748), thus controlling for HLA-C zygosity. This test
demonstrated the effect of HLA-B heterozygosity to be inde-
pendent of HLA-C heterozygosity (P¼ 0.01). The same was
true for HLA-C zygosity (P¼ 0.007 within HLA-B heterozy-
gotes, N¼ 5,933). The independence of locus-specific effects
was also supported when using a linear model that included
the heterozygosity at all three classical HLA class I genes as
independent factors (supplementary table S4, Supplementary
Material online). Moreover, we observed that heterozygosity
at two loci led to better HIV-1 control compared with het-
erozygosity at only one locus (supplementary fig. S2,
Supplementary Material online), in line with previous results
on survival probability (Carrington et al. 1999). Overall, these
results suggest that our data set is appropriate to explore the
effect of HLA heterozygote advantage against HIV and its
underlying mechanism in more detail.
Divergent Allele Advantage
We next sought to test the hypothesis of divergent allele
advantage by evaluating the relation between sequence di-
vergence of an individual’s allele pair and viral load. In our
data set, the number of amino acids that differed between the
antigen-binding domains of an individual’s two homologous
alleles at a given HLA locus ranged from 0 (homozygous
genotypes, i.e., two identical alleles) to 28 (15.5%), 31
(17.1%), and 19 (10.5%) amino acids at HLA-A, HLA-B, and
HLA-C, respectively. In order to capture differences in the
physiochemical properties among amino acids, we calculated
sequence divergence using the Grantham distance score. The
Grantham score is based on differences in physiochemical
properties as well as in the spherical volume among amino
acids, and in an earlier study proved to be the most suitable
proxy for HLA functional divergence among several different
amino acid similarity scores (Pierini and Lenz 2018). First, we
saw that, although zygosity correlated strongly between the
HLA-B locus and the other two HLA class I loci, HLA-C and
HLA-A (s¼ 0.55, P< 1  1064 and s¼ 0.16, P¼ 1.1 
1037, respectively), the sequence divergence between an
individual’s HLA-B alleles was only weakly correlated with
the divergence between HLA-C (s¼ 0.09, P< 0.0001) and
HLA-A alleles (s¼ 0.03, P¼ 0.002) (supplementary fig. S3,
Supplementary Material online). This might suggest both dif-
ferent mutational mechanisms in generating sequence diver-
gence and independent selection processes maintaining
sequence divergence at these loci, in line with selection usu-
ally targeting very specific residues involved in peptide bind-
ing (Reche and Reinherz 2003). Following the predictions of
the divergent allele advantage hypothesis, HLA-B, the locus
with by far the strongest association to HIV control, showed a
negative correlation between pairwise allele divergence and
spVL across individuals (s ¼ 0.08, P¼ 8.6 1020) (fig. 2).
Although we found no such correlation for HLA-A (P¼ 0.77),
HLA-C surprisingly showed a positive association between
allele divergence and viral load (s¼ 0.03, P¼ 4.9  104).
We observed similar correlations after excluding homozygous
individuals (supplementary fig. S4, Supplementary Material
online). In addition, the correlation between viral load and
the interallele divergence at classical HLA class I genes was
supported by their respective effect size calculated using a
linear model in which the sequence divergence between indi-
viduals’ HLA-A, HLA-B, and HLA-C together were taken as
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predictor variables (supplementary table S5, Supplementary
Material online). The coefficients of this linear model also
allowed us to estimate the actual quantitative effect of HLA
allele divergence on viral load. Using data from Pierini and
Lenz (2018), we calculated that one unit of Grantham diver-
gence on average corresponds to about 2.2 amino acids dif-
ference between two HLA class I alleles. With a linear
coefficient of 0.04 for HLA-B divergence (supplementary
table S5, Supplementary Material online), this means that
one amino acid difference between an individual’s two
HLA-B alleles corresponds to a decrease in log HIV-1 RNA
copies per ml blood of about 0.006. It is difficult to judge
whether such a decrease in viral RNA copies provides a sub-
stantial benefit for an infected individual, and whether such
differences could contribute to selection on HLA genes.
However, over evolutionary time-scales, even small selection
coefficients can have significant effects.
Noteworthy with regard to the positive correlation for
HLA-C, alleles of the HLA-C*07 subgroup are known to confer
susceptibility to HIV because of their low expression on the
cell surface (Kulkarni et al. 2011), an effect we can also observe
in our data (supplementary fig. S5A, Supplementary Material
online). Coincidentally, these alleles are also highly divergent
from the rest of the HLA-C alleles (Robinson et al. 2017).
Indeed, individuals carrying an allele of the HLA-C*07 sub-
group have significantly more divergent HLA-C genotypes
than individuals that do not carry such alleles (supplementary
fig. S5B, Supplementary Material online). The higher spVL of
highly divergent HLA-C genotypes might thus be due to low
cell-surface expression of HLA-C, a mechanism unrelated to
the diversity of presented HIV peptides. Notably, even though
HLA-B and HLA-C loci are in strong LD, the pairwise
Grantham distance between individual’s HLA-B alleles was
significantly higher than between HLA-C alleles (P< 0.001)
(supplementary fig. S6, Supplementary Material online), sup-
porting the notion that HLA-C is not evolving under the same
selective constraints as HLA-B. Furthermore, HLA-C generally
does not seem to be under selection for contributing to di-
verse immunological surveillance (Buhler et al. 2016;
Robinson et al. 2017). It is thus possible that this positive
correlation is not due to quantitative differences in antigen
presentation among HLA-C alleles, but due to other mecha-
nisms, for instance variation in cell-surface expression or the
known interactions between HLA-C and Killer-cell
immunoglobulin-like receptor (KIR) (Parham et al. 2012).
Functional Consequence of Heterozygosity and Allele
Divergence
Having observed the effects of both heterozygosity and allele
divergence in our data, we then asked whether these meas-
ures of genetic variability would indeed allow for the presen-
tation of a broader array of HLA-bound peptides, as
hypothesized by the quantitative explanation for MHC het-
erozygote advantage. Using computational peptide-binding
prediction, we found that heterozygosity on average resulted
in a broader array of bound peptides for all three classical HLA
loci (supplementary fig. S7, Supplementary Material online).
Furthermore, the number of peptides bound by a pair of HLA
alleles was positively correlated with the sequence divergence
between the alleles at all three HLA loci (supplementary fig.
S8, Supplementary Material online). This association between
sequence divergence at the HLA loci and predicted functional
divergence among HLA molecule variants has been reported
before (Lenz 2011; Pierini and Lenz 2018). However, our pre-
sent HIV data set allowed us to evaluate this association using
FIG. 1. Viral load in HLA homozygotes and heterozygotes. Comparison of the spVL (log10 HIV-1 RNA copies per ml of plasma) between HLA
homozygous (Hom) and heterozygous (Het) individuals for the three classical HLA class I loci. N indicates the number of individuals. Bonferroni-
corrected P-value from Wilcoxon rank-sum test is shown.
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an empirical disease phenotype. We thus tested whether the
ability to bind more HIV-1 peptides was associated with HIV
control (i.e., spVL). Indeed, the individual-specific number of
HIV-1 peptides predicted to be bound by the individual’s
HLA-B molecules was negatively associated with viral load
(Kendall correlation, s ¼ 0.12, P¼ 1.1  1047) (fig. 3).
This was also true for HLA-A and HLA-C, but correlation
coefficients were smaller (Kendall correlation, HLA-A: s ¼
0.04, P¼ 1.7  105; HLA-C: s ¼ 0.05, P¼ 8.7  108).
The correlation between viral load and predicted number of
HIV-1 peptides presented by classical HLA class I molecules
was supported by their respective effect size calculated using
a linear model in which the number of HIV-1 peptides bound
by individuals’ HLA-A, HLA-B, and HLA-C together were taken
as predictor variables (supplementary table S6,
Supplementary Material online). The linear ß-coefficient for
HLA-B of 0.012 means that each additional HIV-1 peptide
bound by HLA-B leads to a decrease in log HIV-1 RNA copies
per ml blood of about –0.007. Interestingly, the association
between viral load and the breadth of individual-specific pre-
dicted HLA-B bound peptides was stronger (s¼0.12) than
the association between viral load and allele divergence (s ¼
0.08), suggesting that allele divergence is a useful but im-
perfect proxy for functional divergence among HLA-B alleles,
at least in the case of a single pathogen with a limited peptide
repertoire, such as HIV-1.
In order to assure that these results are not biased by the
selected affinity threshold for binding between HLA and
HIV-1 peptides, we evaluated the association of HLA-
bound HIV-1 peptides also with a more stringent and a
more relaxed affinity threshold binding. Here, we observed
an equivalent association between the viral load and the
number of HLA-bound HIV-1 peptides (supplementary fig.
S9, Supplementary Material online). Moreover, given that
some HLA alleles can bind non-9mer peptides, we extended
this analysis to 8mer and 10mer HIV-1 peptides. We ob-
served similar negative associations between viral load and
predicted HLA-bound 10mer peptides (supplementary fig.
S10, Supplementary Material online), but not for 8mer
peptides. This is likely due to the much smaller number
of bound 8mer peptides per HLA allele (median 2 6 3
SD) compared with 9mer (41 6 10) or 10mer (20 6 10)
peptides.
HLA Diversity and Within-Host Evolution of HIV
Presentation of pathogen-derived peptides by HLA molecules
is thought to increase the likelihood and efficiency of a
pathogen-specific immune response. Consequently, such
HLA restriction is a potential factor that might influence
the evolutionary landscape of pathogens. Specifically for
HIV-1, the virus has been shown to acquire mutations within
HLA-bound peptides that can help it to escape immune rec-
ognition (Leslie et al. 2004; Bronke et al. 2013; Arora et al.
2019). In this context, following the predictions of the quan-
titative heterozygote advantage hypothesis, heterozygous
HLA genotypes should exert a broader selective pressure on
the virus, leading to a larger number of escape mutants.
Taking advantage of our unique data set, which also com-
prised a limited set of autologous HIV-1 sequences from a
subset of individuals (N¼ 40, one HIV-1 sequence per indi-
vidual; see Materials and Methods), we performed a phylo-
genetic comparison of these autologous HIV-1 sequences to
test whether HLA heterozygosity leads to more pronounced
sequence evolution, possibly as an adaptation because of the
broader HLA restriction in HLA heterozygous individuals. For
this analysis we focused on HLA-B, the locus with strongest
association with HIV control, and observed that autologous
virus sequences in HLA-B heterozygous individuals (N¼ 36)
show indeed higher sequence diversity than the ones in ho-
mozygous individuals (N¼ 4; HIV diversity measured as root-
to-tip distance, fig. 4A and B). In order to account for the
unbalanced sample size, we permuted the individuals across
zygosity groups for 10,000 times and each time recalculated
the average root-to-tip distances. This analysis showed that
the observed difference was unlikely to be due to chance
(one-tailed P¼ 0.027) (supplementary fig. S11,
Supplementary Material online). However, the bias in the
sample sizes from the small number of homozygous subjects
FIG. 2. Sequence divergence between individual’s HLA alleles and viral load. Correlation between spVL (log10 HIV-1 RNA copies per ml of plasma)
and sequence divergence between individual’s HLA-A, HLA-B, and HLA-C alleles is shown (including homo- and heterozygotes; N¼ 6,311). The
color indicates the density of individuals. Kendall’s estimate of correlation s and Bonferroni-corrected P-value are shown.
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remains a problem for this analysis. We therefore tested the
above prediction also in a different approach that is not ham-
pered by biased sample sizes. For this, we tested the effect of
the overall breadth of HLA-presented peptides on virus evo-
lution. Again, HLA genotypes that allow presentation of a
broader set of HIV-1 peptides should lead to more pro-
nounced evolution in the virus. Accordingly, we observed a
positive correlation between the total number of predicted
HLA-bound peptides and the diversity of HIV sequences
among individuals for which autologous HIV sequence data
were available (N¼ 40) (fig. 4C). In a previous analysis of these
data, we already identified six mutations in HIV-1 that were
predicted to evade peptide presentation by the variant HLA-
B*57:01 (Arora et al. 2019), likely contributing to the elevated
sequence diversity in HLA heterozygotes observed here.
Nonetheless, more autologous HIV-1 sequences, particularly
from HLA homozygous individuals, will help to corroborate
these findings.
Allele-Specific Effects versus General Heterozygote
Advantage
HLA alleles are known to show differential association with
HIV-1 control ranging from risk to protection (McLaren et al.
2015). We therefore tested the alternative hypothesis for het-
erozygote advantage, which suggests that heterozygosity
might simply increase the chances of carrying a particular
HLA allele that binds immunogenic peptides and through
that provides better viral control. Of seven HLA-B alleles sig-
nificantly associated with HIV control, four (including
B*57:01) were indeed enriched in the heterozygous state (sup-
plementary fig. S12, Supplementary Material online), making
this hypothesis a viable explanation. The nonsignificant en-
richment for the other three alleles could be due to their low
frequency in our data set. We then asked what property
made individual alleles more protective. Following the same
intuition as for the quantitative heterozygote advantage
above, they could confer protection simply by presenting
FIG. 3. HLA-bound peptides and viral load (spVL). Correlation between individual’s spVL (log10 HIV-1 RNA copies/ml of plasma) and the breadth
of HIV-1 peptides predicted to be bound by the individual’s HLA-A, HLA-B, and HLA-C alleles is shown (including homo- and heterozygotes;
N¼ 6,311). The color indicates the density of individuals. Kendall’s estimate of correlation s and Bonferroni-corrected P-value are shown.
FIG. 4. Evolution of HIV sequence diversity in response to HLA-B diversity. (A) Rooted phylogenetic trees of autologous virus sequences (blue dots)
from HLA-B homozygous (N¼ 4) and heterozygous (N¼ 36) individuals. We used HIV-2 (red dot) as outgroup to identify the root during tree
construction. (B) Virus sequences exhibit higher sequence diversity (measured root-to-tip patristic distance, i.e., sum of branch lengths) among
HLA-B heterozygous individuals (blue dots) compared with homozygotes (yellow dots). N indicates the number of individuals. (C) The number of
predicted HLA-B bound peptides correlates positively with the diversity of HIV sequences among individuals (N¼ 40, correlation coefficient s and
P-value from Kendall rank correlation are shown).
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more peptides to T cells compared with other alleles.
Alternatively, they could confer a qualitative advantage by
presenting very specific peptides that are particularly difficult
(i.e., costly in terms of fitness) for the virus to mutate. We
tested this point by focusing on HLA-B*57:01, the allele known
to confer the strongest resistance against disease progression
(Migueles et al. 2000; Bailey et al. 2006; Pohlmeyer et al. 2013;
McLaren et al. 2015). We found that heterozygous individuals
with the allele B*57:01 exhibited a lower viral load than het-
erozygotes without this allele (carrying any two HLA-B alleles
except B*57:01) (Wilcoxon rank sum test, P< 0.001; fig. 5A).
However, heterozygotes with B*57:01 are also predicted to
bind a greater breadth of peptides compared with heterozy-
gous individuals without B*57:01 (Wilcoxon rank sum test,
P< 0.001; fig. 5B), making it difficult to discern quantitative
and qualitative effects of B*57:01. Yet, homozygotes with the
allele B*57:01 alone were predicted to bind fewer HIV-1 pep-
tides (54 peptides) than heterozygotes without this allele
(binding a median of 68 peptides; Wilcoxon rank sum test,
P¼ 0.003; fig. 5B). This allowed us to evaluate the qualitative
effect of B*57:01 in binding specific HIV peptides on viral load
while excluding any quantitative advantage of binding more
HIV peptides. We found that individuals homozygous for
B*57:01 still exhibited a lower viral load than B*57:01/
heterozygotes (Wilcoxon rank sum test, P¼ 0.011) (fig. 5A),
despite the fewer peptides they can present, suggesting that
binding of specific HIV-1 peptides provides a qualitative ad-
vantage to B*57:01. Nevertheless, B*57:01 is also predicted to
bind a higher than average number of HIV-1 peptides among
all tested HLA-B alleles (Arora et al. 2019), maintaining the
possibility that both qualitative and quantitative aspects of
peptide binding are contributing to the protective effect of
this allele.
Having established that the effect of individual HLA alleles
can significantly exceed the effect of general zygosity, we next
aimed to explore more generally the relative role of additive
effects of HLA-B alleles versus HLA-B heterozygosity. An inde-
pendent advantageous effect of HLA-B heterozygosity had
already been shown in a previous fine-mapping study
(McLaren et al. 2015). Here, we therefore compared the ob-
served association of HLA heterozygosity with spVL to the
effects of HLA sequence divergence and the number of bound
HIV-1 peptides after accounting for the additive effect of
individual HLA-B alleles. Using a regression model that in-
cluded allele-specific effects in an additive manner, we ob-
served qualitatively equivalent effects of HLA heterozygosity,
sequence divergence, and the number of predicted HLA-
bound peptides on viral load as in the absence of allele-
specific effects, with a variation in viral load associated with
these compound parameters ranging from 0.06% to 0.09%
(table 1). Noteworthy, the beneficial effect of heterozygosity
remains significant overall, even though we found above that
there is no significant difference in viral load between homo-
zygotes and heterozygotes among carriers of the allele HLA-
B*57:01, likely because of the dominant protective effect of
this particular allele. This suggests in turn that heterozygosity
is even more beneficial among carriers of other alleles than
shown by these numbers. However, it is also apparent that
the independent effect of these compound parameters is
substantially lower than the combined additive effects of all
individual HLA-B alleles, which account for 11.4% of the var-
iation in viral load (McLaren et al. 2015). Interestingly, after
including allele-specific additive effects, which account for the
allele-specific HIV-1 peptide repertoire size, the effect of HLA-
B sequence divergence and predicted combined number of
bound HIV-1 peptides becomes very similar. This suggests
FIG. 5. Heterozygote advantage versus allele-specific effect for HLA-B*57:01. Variation in (A) set point viral load (spVL, log10 HIV-1 RNA copies/ml
of plasma) and (B) the number of HIV-1 peptides bound by HLA-B in HLA heterozygous individuals not carrying HLA-B*57:01 (B57:01/),
individuals carrying one copy of HLA-B*57:01 (B57:01þ/), and individuals homozygous for HLA-B*57:01 (B57:01þ/þ). N indicates the number of
individuals. Bonferroni-corrected P-values from Wilcoxon rank sum test are shown.
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that allele divergence (here measured as Grantham distance)
is a useful proxy for the overlap in binding properties, that is,
the redundancy in presented peptides between two HLA
alleles.
Discussion
Of all three classical HLA class I genes tested here, heterozy-
gosity at HLA-B and HLA-C was independently associated
with viral control. The absence of a significant association
with HLA-A heterozygosity that contrasts with a previously
observed association between HLA-A heterozygosity and dis-
ease progression (Carrington et al. 1999) might either be ow-
ing to its genetic linkage (LD) with neighboring HLA-B and/or
HLA-C loci (Ahmad et al. 2003; Stenzel et al. 2004; Blomhoff
et al. 2006) or the different disease parameters used (progres-
sion over time vs. spVL). However, the absence of a statisti-
cally significant association between sequence variation at
HLA-A and HIV-1 viral load might also suggest that HLA-A
is not a prime target of pathogen-mediated selection, which
was already proposed earlier and is supported by the con-
served profile of HLA-A residues involved in peptide binding
(dos Santos Francisco et al. 2015). We also recapitulated the
observation that higher sequence divergence between an
HLA allele pair generally could lead to a larger number of
bound peptides, but here focusing only on HIV peptides
(Lenz 2011; Pierini and Lenz 2018). The weaker association
of sequence divergence with HIV-1 viral load suggests that the
number of bound peptides, where available, could be a better
proxy for immunocompetence when focusing on a specific
pathogen, particularly if it has a small proteome as was the
case here.
The negative correlation between the number of HLA-B-
bound peptides and viral load among individuals suggests
that HLA-B heterozygote advantage is significantly mediated
via quantitative CTL response to a broad set of HLA-
presented HIV-1 peptides, though empirical validation would
substantiate the finding. Interestingly, a relatively weak nega-
tive correlation between HLA-C bound peptides and viral load
suggests that an effector mechanism other than CTL-
mediated quantitative immune response might be responsi-
ble for HLA-C heterozygote advantage. This suggestion gains
additional support from the fine-mapping study by McLaren
et al. (2015), where unlike for HLA-B, there were no
HIV-associated amino acid residues found for HLA-C.
Moreover, with only about half the peptide-repertoire size
of HLA-C alleles, relative to HLA-A and HLA-B, HLA-C might
be evolving not to interact with the vast diversity of CTLs, but
other relatively less diverse cell types. One such cell type could
be natural killer cells which express KIRs on their cell surface
(Parham 2005). HLA-C molecules are thought to be a potent
ligand of KIRs (Colonna et al. 1993; Parham 2005; Hilton et al.
2015), and specific interactions between HLA-C molecules
and KIRs have been associated with multiple diseases, includ-
ing HIV infection (Rajagopalan and Long 2005; Zipeto and
Beretta 2012; Körner et al. 2017).
Pereyra et al. (2014) have shown that CD8þ T-cell targeting
of specific HLA-presented peptides could confer viral control
(Pereyra et al. 2014). A broader array of HLA-bound peptides
in heterozygous individuals might increase the possibility that
such peptides are presented on the cell surface. However, the
particular case of the B*57:01 allele conferring superior viral
control compared with general HLA-B heterozygote advan-
tage suggests that HLA allele-specific effects might arise from
binding specific immunodominant peptides. Nevertheless, as
B*57:01 also bound the largest number of peptides among all
HLA-B alleles, the quantitative advantage of binding a large
number of peptides might contribute to its strong protective
effect in HIV-1 control.
Together, these results suggest that HLA heterozygosity in
an individual might confer advantage in multiple, possibly
additive ways. One is the quantitative advantage through
presentation of a larger number of viral peptides, which might
generate a broader immune response. This appears to exert
stronger evolutionary pressure on the virus to evolve, as
shown by elevated sequence diversity of the virus among
HLA heterozygous individuals, possibly resulting in replicative
fitness cost. In addition, HLA heterozygosity might provide an
advantage by making it more likely to carry certain protective
HLA alleles that can present immunodominant peptides to T
cells and thus lead to disease control.
In conclusion, our findings shed light on the functional
basis of the protective association between HLA hetero-
zygosity and HIV control. Interestingly, heterozygote ad-
vantage is generally thought to be more important in a
multiparasite context, with HLA heterozygosity assumed
to enable hosts to recognize and fight more different
parasites (Penn et al. 2002). It is certainly conceivable
that in such a multiparasite context, quantitative aspects
of antigen presentation become more important than
qualitative aspects due to the sheer number of peptides
involved. Nevertheless, our study demonstrates and char-
acterizes HLA gene-specific heterozygote advantage even
against a single pathogen. The findings disentangle the
role of quantitative and qualitative features of the
HLA’s peptide repertoire in mediating the immune
response and suggest that even a single pathogen can
lead to selection for both HLA heterozygosity (including
excessive allele divergence) and specific HLA alleles.
Moreover, they lend support to HIV vaccine programs
aiming to impart antiviral immunity using a broad, yet
specific array of HIV peptides.
Table 1. Variation in HIV-1 set point viral load (spVL) associated with
different measures of HLA-B diversity before and after accounting for
allele-specific additive effects.





Heterozygosity 0.3 (6.6 3 1026) 0.06 (0.016)
Sequence divergence 1.3 (1.0 3 10220) 0.09 (0.005)
Bound peptides 3.3 (2.6 3 10250) 0.09 (0.006)
NOTE.—Effect of HLA-B heterozygosity, sequence divergence between individual
HLA-B alleles, and breadth of predicted HLA-B bound HIV-1 peptides is shown.
P-values from linear regression models are given in parentheses (N¼ 6,311).
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Materials and Methods
Samples and Genotype Data
We used HLA genotyping and clinical data from 6,311 chron-
ically HIV-1-infected individuals that were previously analyzed.
HLA genotype imputation and quality control are described in
detail in McLaren et al. (2015). Briefly, genome-wide single
nucleotide polymorphism (SNP) genotype data were collected
from eight genome-wide association studies mentioned in sup-
plementary table S7, Supplementary Material online. Originally,
the data were sequenced in 21 cohorts across Australia,
Europe, and the United States participating in the
International Collaboration for the Genomics of HIV, through
which the data can be accessed. SNP genotypes absent in
original genotyping platforms were imputed (McLaren et al.
2015). Imputed SNPs with low imputation quality (R2 score<
0.3) or minor allele frequency of <0.5% were discarded. HLA
alleles (at second-field resolution) for classical class I loci (HLA-
A, HLA-B, HLA-C) were imputed as best-guess genotypes from
genome-wide genotype data using the SNP2HLA method (Jia
et al. 2013) and a reference panel consisting of 5,225 individuals
of European ancestry from the Type-1 Diabetes Genetics
Consortium (T1DGC) (Rich et al. 2006). Following an estab-
lished HLA imputation procedure, individuals whose alleles
scored a robust R2 (imputation quality score) >0.8 were
retained, yielding a data set with 6,311 individuals with a total
of 37 HLA-A, 69 HLA-B, and 27 HLA-C alleles. Pretreatment
HIV-1 spVL (log10 HIV-1 RNA copies/ml of plasma) was used
as a quantitative disease phenotype (McLaren et al. 2015).
HLA Binding Affinity for HIV-1 Peptides
Following Arora et al. (2019), we used the reference proteome
of HIV-1 M group subtype B (NCBI accession number
NC_001802.1) that comprised ten proteins. The Gag–Pol pro-
tein is a precursor protein resulting from a 1 ribosomal
frameshifting event in upstream Gag (Jacks et al. 1988), and
then cleaved by the virus-encoded protease to produce the
mature Pol protein. In order to avoid redundancy with the
separate Gag protein in our analysis, we manually trimmed
the Gag–Pol protein sequence to Pol. HLA class I molecules
preferentially bind and present 9mer peptides (Falk et al.
1991; York et al. 2002). We used a computational method
called NetMHCpan v4.0 (Jurtz et al. 2017) to predict the
binding affinity of all possible 9mer peptides derived from
the entire HIV-1 proteome to individual HLA class I alleles
represented in our data set. The method reports the rank of
predicted binding affinity of HLA-peptide complexes against
predicted affinity of random natural peptides. HLA-peptide
complexes with predicted binding affinity rank <0.5 were
retained (corresponding to “strongly bound” peptides)
(Jurtz et al. 2017). The breadth of peptides bound by an
individual’s HLA allele pair was taken as the total number
of unique peptides predicted to be bound by both alleles.
Sequence Divergence between Alleles of HLA
Genotype per Individual
Sequence divergence between alleles was computed for all
HLA allele pairs (genotypes) of HLA-A, HLA-B, and HLA-C loci.
Protein sequences of HLA alleles were taken from IMGT/HLA
database (Robinson et al. 2015). Exons 2 and 3, which encode
the variable region in the peptide-binding groove of HLA class
I molecules, were obtained following the exon annotation
reported in Ensemble database (Aken et al. 2016). The align-
ment of amino acid sequences was performed using MUSCLE
(Edgar 2004). The genetic distances between aligned allele
pairs were calculated based on the Grantham distance matrix
(Grantham 1974) using a custom Perl script freely available
online (Pierini and Lenz 2018). The nonparametric Kendall
correlation was used to test for the associations of the se-
quence divergence between individual’s HLA alleles with 1)
spVL and 2) the combined number of predicted HLA-bound
peptides. All P-values were adjusted for multiple testing
across the number of loci tested.
Phylogenetic Comparison of Autologous Virus
Sequences
Autologous amino acid sequences of six HIV-1 proteins,
namely Gag, Pol, Vif, Vpr, Vpu, and Nef, were obtained from
bulk sequencing of viral RNA as described in Bartha et al.
(2013) and available for 65 individuals (one consensus se-
quence per individual). Due to fragmented coverage of
sequences, we concatenated these six proteins in order to
obtain better resolution and statistical power and aligned
them using MAFFT v7 with default parameters (Katoh
et al. 2002). However, the viral sequences were too frag-
mented (missing sequence information), and this introduced
several gaps in their alignment. Therefore, we optimized the
alignment for maximum gap-free area by selecting an optimal
subset of sequences using MaxAlign-1.1 (Gouveia-Oliveira
et al. 2007), which resulted in sequence data from 4 HLA-B
homozygous and 36 heterozygous individuals (one autolo-
gous sequence each). Maximum likelihood trees were made
using PhyML-3.1 (Guindon and Gascuel 2003) with default
parameters. The tip-to-tip distances were extracted using
Ape-3.5 package (Paradis et al. 2004) in R 3.5.1. Using HIV-2
as an outgroup, the root-to-tip distance was used as a proxy
for evolutionary diversity among host-specific HIV-1 clones.
Difference in the mean root-to-tip distance in each group of
individuals was taken as the observed difference in diversity.
We obtained statistical significance of the observed difference
by permuting the individuals across the groups and repeating
the above procedure 10,000 times. P-value was taken as the
fraction of permutations where the difference in mean diver-
gence was equal to or more than the observed difference.
Association with Viral Load While Controlling for
Allele-Specific Effects
The association of a variable with spVL was calculated using a
linear regression model following McLaren et al. (2015).
Variation in spVL attributable to a given variable (heterozy-
gosity, sequence divergence, or the breadth of predicted HLA-
bound peptides) while controlling for allele-specific effects
was taken as the difference between adjusted-R2 values of
the model with variable, alleles and covariates (eq. 1)
and the model with alleles and covariates only (eq. 2). We
did the analysis for each classical HLA class I locus separately.
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Models contained all imputed alleles (N¼ 69 for HLA-B,
N¼ 37 for HLA-A, N¼ 27 for HLA-C), the first five principle
components of SNP variation, and the cohort identity (all
adopted from McLaren et al. [2015]) as the covariates. The
significance of the variable’s association with viral load was
calculated by comparing these two models using chi-square
test.
spVL ¼ b1  variable þ
XN
i¼1
bi  allelei þ b2  covariates þ e1; (1)
spVL ¼ b1  variable þ
XN
i¼1
bi  allelei þ b2  covariates þ e2: (2)
All analyses were performed in R v3.5.1, and data were
visualized using the ggplot2 v2.2.1 package (Wickham 2009).
Supplementary Material
Supplementary data are available at Molecular Biology and
Evolution online.
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allele promiscuity revisited. Immunogenetics 63(11):691–701.
Reche PA, Reinherz EL. 2003. Sequence variability analysis of human class
I and class II MHC molecules: functional and structural correlates of
amino acid polymorphisms. J Mol Biol. 331(3):623–641.
Rich SS, Concannon P, Erlich H, Julier C, Morahan G, Nerup J, Pociot F,
Todd JA. 2006. The Type 1 Diabetes Genetics Consortium. Ann N Y
Acad Sci. 1079(1):1–8.
Richman AD, Herrera LG, Nash D. 2001. MHC class II beta
sequence diversity in the deer mouse (Peromyscus maniculatus):
implications for models of balancing selection. Mol Ecol.
10(12):2765–2773.
Robinson J, Guethlein LA, Cereb N, Yang SY, Norman PJ, Marsh SGE,
Parham P. 2017. Distinguishing functional polymorphism from ran-
dom variation in the sequences of>10, 000 HLA-A, -B and -C alleles.
PLoS Genet. 13:e1006862.
Robinson J, Halliwell JA, Hayhurst JD, Flicek P, Parham P, Marsh S. 2015.
The IPD and IMGT/HLA database: allele variant databases. Nucleic
Acids Res. 43(D1):D423–D431.
Schwensow N, Eberle M, Sommer S. 2010. Are there ubiquitous parasite-
driven major histocompatibility complex selection mechanisms in
gray mouse lemurs? Int J Primatol. 31(4):519–537.
Solberg OD, Mack SJ, Lancaster AK, Single RM, Tsai Y, Sanchez-
Mazas A, Thomson G. 2008. Balancing selection and
HLA Heterozygote Advantage against HIV-1 . doi:10.1093/molbev/msz249 MBE
649
heterogeneity across the classical human leukocyte antigen loci:
a meta-analytic review of 497 population studies. Hum
Immunol. 69(7):443–464.
Sommer S. 2005. The importance of immune gene variability (MHC) in
evolutionary ecology and conservation. Front Zool. 2:1–18.
Spurgin LG, Richardson DS. 2010. How pathogens drive genetic diversity:
MHC, mechanisms and misunderstandings. Proc R Soc B Biol B.
277(1684):979–988.
Stenzel A, Lu T, Koch WA, Hampe J, Guenther SM, de la Vega FM,
Krawczak M, Schreiber S. 2004. Patterns of linkage disequilibrium
in the MHC region on human chromosome 6p. Hum Genet.
114(4):377–385.
Stutz WE, Bolnick DI. 2017. Natural selection on MHC IIb in parapatric
lake and stream stickleback: balancing, divergent, both or neither?
Mol Ecol. 26(18):4772–4786.
Takeshima S, Matsumoto Y, Chen J, Yoshida T, Mukoyama H, Aida Y.
2008. Evidence for cattle major histocompatibility complex (BoLA)
class II DQA1 gene heterozygote advantage against clinical mastitis
caused by Streptococci and Escherichia species. Tissue Antigens
72(6):525–531.
Trowsdale J. 2011. The MHC, disease and selection. Immunol Lett. 137(1–
2):1–8.
Trowsdale J, Knight JC. 2013. Major histocompatibility complex genomics
and human disease. Annu Rev Genomics Hum Genet. 14(1):301–323.
Wakeland E, Boehme S, She J, Lu C, McIndoe R, Cheng I, Ye Y, Potts W.
1990. Ancestral polymorphisms of MHC class II genes: divergent
allele advantage. Immunol Res. 9(2):115–122.
Wickham H. 2009. ggplot2: Elegant Graphics for Data Analysis. Springer-
Verlag New York. [https://CRAN.R-project.org/package=ggplot]
York IA, Chang SC, Saric T, Keys JA, Favreau JM, Goldberg AL, Rock KL.
2002. The Er aminopeptidase ERAP I enhances or limits antigen
presentation by trimming epitopes to 8-9 residues. Nat Immunol.
3(12):1177–1184.
Zipeto D, Beretta A. 2012. HLA-C and HIV-1: friends or foes?
Retrovirology 9(1):39.
Arora et al. . doi:10.1093/molbev/msz249 MBE
650
